아스페르길루스증 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 약제 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁별 부문(2020-2030F)
Aspergillosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1703272
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 아스페르길루스증 시장은 2024년에 46억 3,000만 달러로 평가되고, 2030년에는 58억 7,000만 달러에 달할 것으로 예측되며, 예측 기간 중 연평균 성장률(CAGR)은 4.02%로 성장할 것으로 예측됩니다.
이 시장은 아스페르길루스 관련 진균 감염증에 대한 대응에 초점을 맞추고 있는 헬스케어 분야에 필수적인 시장입니다. 아스페르길루스증은 아스페르길루스 종에 의해 발생하는 질환군으로, 침습성 아스페르길루스증은 가장 심각한 질환으로 장기이식 환자나 화학요법을 받는 환자 등 면역력이 저하된 사람에게 주로 발생합니다. 이 시장은 이러한 감염증을 관리하고 예방하기 위한 광범위한 진단, 치료, 예방 솔루션을 포괄하고 있습니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
46억 3,000만 달러
시장 규모 : 2030년
58억 7,000만 달러
CAGR : 2025-2030년
4.02%
급성장 부문
Isavuconazole
최대 시장
북미
시장 성장의 주요 요인은 HIV/AIDS의 발병률 증가, 장기이식, 면역억제요법의 보급 등으로 인해 면역 결핍 환자가 증가하고 있다는 점입니다. 이에 따라 조기 발견과 신속한 치료를 가능하게 하는 PCR 분석, 항원 검사, CT 스캔과 같은 영상 진단 기술을 포함한 첨단 진단 툴에 대한 수요가 급증하고 있습니다.
Global Aspergillosis Market was valued at USD 4.63 billion in 2024 and is projected to reach USD 5.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.02% during the forecast period. This market is an integral part of the healthcare sector, focusing on addressing the challenges posed by Aspergillus-related fungal infections. Aspergillosis is a group of diseases caused by the Aspergillus species, with invasive aspergillosis being the most severe form, predominantly affecting individuals with weakened immune systems, such as organ transplant recipients and patients undergoing chemotherapy. The market encompasses a broad range of diagnostic, therapeutic, and preventive solutions designed to manage and combat these infections.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 4.63 Billion
Market Size 2030
USD 5.87 Billion
CAGR 2025-2030
4.02%
Fastest Growing Segment
Isavuconazole
Largest Market
North America
A primary driver of market growth is the increasing prevalence of immunocompromised individuals, fueled by rising rates of HIV/AIDS, organ transplants, and the expanded use of immunosuppressive therapies. This has led to a surge in demand for advanced diagnostic tools, including PCR assays, antigen testing, and imaging techniques such as CT scans, which enable early detection and prompt treatment.
Key Market Drivers
Rising Incidence of Immunocompromised Patients
The growth of the global aspergillosis market is significantly influenced by the rising number of immunocompromised patients. Individuals with conditions such as HIV/AIDS, those undergoing organ transplants, and patients receiving immunosuppressive therapies are particularly vulnerable to Aspergillus-related infections. In 2023, approximately 39.9 million people globally were living with HIV, with 1.3 million new infections reported that year. In the United States, an estimated 3% of adults are immunocompromised due to immune-affecting conditions or treatments. Additionally, 172,409 organ transplants were conducted worldwide in 2023, a 9.5% increase from the previous year. These statistics underscore the growing population of immunocompromised individuals, driving demand for diagnostics and treatments for infections like aspergillosis.
Studies also show that immunocompromised patients face a heightened risk of severe infections, including those caused by SARS-CoV-2, highlighting the need for specialized care and preventive strategies. This trend emphasizes the need for tailored therapies and enhanced healthcare infrastructure to meet the unique needs of these patients, further propelling market expansion in the aspergillosis sector.
Key Market Challenges
Limited Awareness and Underdiagnosis
A significant challenge faced by the global aspergillosis market is the lack of awareness and underdiagnosis of Aspergillus-related infections. Despite the severe health risks associated with aspergillosis, it remains relatively unknown outside specialized medical circles. Many healthcare professionals, and the general public, are unfamiliar with the symptoms and risks of this fungal infection, which can often mimic other respiratory conditions, leading to misdiagnosis or delays in diagnosis. This lack of timely diagnosis can result in suboptimal or incorrect treatment, affecting patient outcomes and hindering market growth.
Furthermore, underdiagnosis-an issue stemming from limited awareness-poses a serious concern. Without early intervention, aspergillosis can progress from a treatable condition to a life-threatening disease, particularly in immunocompromised individuals. The absence of widespread educational campaigns means that high-risk populations, such as organ transplant recipients or those undergoing immunosuppressive therapies, may not receive proper screening or information. These challenges create missed opportunities for market development and the timely delivery of critical treatments.
Key Market Trends
Immunomodulatory Therapies
Immunomodulatory therapies are emerging as a key growth driver in the global aspergillosis market. These therapies, designed to modulate and enhance the immune response, offer a promising adjunctive approach to managing aspergillosis, particularly in immunocompromised individuals. For patients with weakened immune systems-such as transplant recipients, chemotherapy patients, and those with underlying immunodeficiencies-the risk of invasive aspergillosis is significantly elevated. Immunomodulatory agents like granulocyte colony-stimulating factors (G-CSF) and interferon-gamma are being studied for their potential to stimulate the immune system and help patients better combat fungal infections.
Clinical trials have demonstrated that immunomodulatory therapies, when used alongside traditional antifungal treatments, can significantly improve patient outcomes by enhancing immune function. These therapies not only aid in controlling current infections but also reduce the risk of recurrence, which is a common concern in aspergillosis management. As the benefits of immunomodulatory therapies become increasingly recognized, healthcare providers are incorporating them into treatment regimens, stimulating further market growth as pharmaceutical companies invest in developing targeted therapies tailored to the needs of aspergillosis patients.
Key Market Players
Pfizer Inc
Therma Fisher Scientific
Rewine Pharmaceuticals
Teva Pharmaceuticals
Eugia Pharma
krishlar Pharmaceuticals
Merck KGA
Aozeal
Hikma
Xellia Pharmaceuticals
Report Scope:
In this report, the Global Aspergillosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Aspergillosis Market, By Type:
Chronic Pulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis (ABPA)
Invasive Aspergillosis
Aspergillosis Market, By Drug Type:
Isavuconazole
Voriconazole
Amphotericin-B
Itraconazole
Corticosteroids
Posaconazole
Others
Aspergillosis Market, By Route of Administration:
Oral
Intravenous
Aspergillosis Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Aspergillosis Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Aspergillosis Market.
Available Customizations:
Global Aspergillosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Aspergillosis Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Invasive Aspergillosis)
4.2.2. By Drug Type (Isavuconazole, Voriconazole, Amphotericin-B, Itraconazole, Corticosteroids, Posaconazole, Others)
4.2.3. By Route of Administration (Oral, Intravenous)
4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.5. By Region
4.2.6. By Company (2024)
4.3. Market Map
4.3.1. By Type
4.3.2. By Drug Type
4.3.3. By Route of Administration
4.3.4. By Distribution Channel
4.3.5. By Region
5. Asia Pacific Aspergillosis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Drug Type
5.2.3. By Route of Administration
5.2.4. By Distribution Channel
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Aspergillosis Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Drug Type
5.3.1.2.3. By Route of Administration
5.3.1.2.4. By Distribution Channel
5.3.2. India Aspergillosis Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Drug Type
5.3.2.2.3. By Route of Administration
5.3.2.2.4. By Distribution Channel
5.3.3. Australia Aspergillosis Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Drug Type
5.3.3.2.3. By Route of Administration
5.3.3.2.4. By Distribution Channel
5.3.4. Japan Aspergillosis Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Drug Type
5.3.4.2.3. By Route of Administration
5.3.4.2.4. By Distribution Channel
5.3.5. South Korea Aspergillosis Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Drug Type
5.3.5.2.3. By Route of Administration
5.3.5.2.4. By Distribution Channel
6. Europe Aspergillosis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Type
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Aspergillosis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Type
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Germany Aspergillosis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Type
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Spain Aspergillosis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Type
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
6.3.4. Italy Aspergillosis Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Drug Type
6.3.4.2.3. By Route of Administration
6.3.4.2.4. By Distribution Channel
6.3.5. United Kingdom Aspergillosis Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Drug Type
6.3.5.2.3. By Route of Administration
6.3.5.2.4. By Distribution Channel
7. North America Aspergillosis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. Type
7.2.3. By Distribution Channel
7.2.4. By Route of Administration
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Aspergillosis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Aspergillosis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Aspergillosis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. South America Aspergillosis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Drug Type
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Aspergillosis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Argentina Aspergillosis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Colombia Aspergillosis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
9. Middle East and Africa Aspergillosis Market Outlook
